My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 136

    1.

    Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

    Zeuzem S.

    Ann Intern Med. 2004 Mar 2;140(5):370-81. Review.PMID: 14996679 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

    Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.PMID: 15461877 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

    Shiffman ML.

    Curr Gastroenterol Rep. 2006 Feb;8(1):46-52. Review.PMID: 16510034 [PubMed - indexed for MEDLINE]Related articles

    4.

    Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team.

    N Engl J Med. 2004 Jul 29;351(5):451-9.PMID: 15282352 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.

    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.

    J Viral Hepat. 2007 Oct;14(10):721-9.PMID: 17875007 [PubMed - indexed for MEDLINE]Related articles

    6.

    Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.

    Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H.

    Dig Dis Sci. 2005 Apr;50(4):719-26.PMID: 15844708 [PubMed - indexed for MEDLINE]Related articles

    7.

    Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.

    Malone DC, Tran TT, Poordad FF.

    J Manag Care Pharm. 2005 Oct;11(8):687-94.PMID: 16194133 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.

    Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O.

    Scand J Gastroenterol. 2007 Feb;42(2):247-55.PMID: 17327945 [PubMed - indexed for MEDLINE]Related articles

    9.

    Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

    del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.

    AIDS. 2008 May 11;22(8):923-30.PMID: 18453851 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Treatment of hepatitis C virus infection]

    Zeuzem S.

    Praxis (Bern 1994). 2005 May 4;94(18):721-6. Review. German. PMID: 15938383 [PubMed - indexed for MEDLINE]Related articles

    11.

    Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

    New Microbiol. 2005 Jan;28(1):13-21.PMID: 15782622 [PubMed - indexed for MEDLINE]Related articles

    12.

    Chronic hepatitis C: management of treatment failures.

    Keeffe EB.

    Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S102-5. Review.PMID: 16234055 [PubMed - indexed for MEDLINE]Related articles

    13.

    Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.

    Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

    Drugs. 2008;68(6):791-801.PMID: 18416586 [PubMed - indexed for MEDLINE]Related articles

    14.

    Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

    Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

    Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210. PMID: 18081356 [PubMed - indexed for MEDLINE]Related articles

    15.

    The evolving treatment of chronic hepatitis C: where we stand a decade out.

    Saadeh S, Davis GL.

    Cleve Clin J Med. 2004 May;71 Suppl 3:S3-7. Review.PMID: 15468610 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

    J Gastroenterol Hepatol. 2007 May;22(5):669-75.PMID: 17444854 [PubMed - indexed for MEDLINE]Related articles

    17.

    Management of patients with chronic hepatitis C virus infection and previous nonresponse.

    Shiffman ML.

    Rev Gastroenterol Disord. 2004;4 Suppl 1:S22-30. Review.PMID: 15184821 [PubMed - indexed for MEDLINE]Related articles

    18.

    Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.

    Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.

    Liver Int. 2007 Sep;27(7):954-9.PMID: 17696934 [PubMed - indexed for MEDLINE]Related articles

    19.

    Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

    Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

    J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. Epub 2008 Apr 19.PMID: 18422960 [PubMed - indexed for MEDLINE]Related articles

    20.

    Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.

    Poo JL, Sánchez-Avila F, Kershenobich D, García-Samper X, Gongora J, Uribe M.

    J Gastroenterol Hepatol. 2004 Dec;19 Suppl 6:S79-81.PMID: 15546256 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity